The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tolerability of neratinib in older adults with HER2 positive or HER2 mutated metastatic breast cancer.
 
Jin Sun Lee
No Relationships to Disclose
 
Susan Elaine Yost
No Relationships to Disclose
 
Tracey Stiller
No Relationships to Disclose
 
Suzette Blanchard
No Relationships to Disclose
 
Simran Padam
No Relationships to Disclose
 
Vani Katheria
No Relationships to Disclose
 
Aileen Tang
No Relationships to Disclose
 
Norma Martinez
No Relationships to Disclose
 
Niki Himat Patel
No Relationships to Disclose
 
Mina S. Sedrak
Research Funding - Novartis (Inst); Seagen (Inst)
 
James Ross Waisman
No Relationships to Disclose
 
Daneng Li
Consulting or Advisory Role - Bayer; Eisai; Exelixis; Genentech; Ipsen; Lexicon; Taiho Pharmaceutical
Speakers' Bureau - Advanced Accelerator Applications; Eisai; Exelixis; Ipsen; Lexicon
Research Funding - Brooklyn ImmunoTherapeutics (Inst)
 
Shamel Sanani
No Relationships to Disclose
 
Cary A. Presant
Stock and Other Ownership Interests - Cancer Diagnostics of America
Consulting or Advisory Role - Cancer Diagnostics of America
Patents, Royalties, Other Intellectual Property - Patent pending for "A Method and Devices for Direct Apoptosis of Purified Cells"
(OPTIONAL) Uncompensated Relationships - Cancer Diagnostics of America
 
Joanne E. Mortimer
Honoraria - Novartis
Consulting or Advisory Role - Karyopharm Therapeutics; Novartis; Puma Biotechnology
 
Yuan Yuan
Consulting or Advisory Role - Eisai; Genentech; Immunomedics; Novartis; Pfizer
Speakers' Bureau - Eisai; Genentech
Research Funding - Eisai; Genentech; Merck; Novartis; Pfizer; Puma Biotechnology
Expert Testimony - Novartis